You are here: Home » Reuters » News
Business Standard

Sanofi and Regeneron boost investment in cancer drug cemiplimab

Reuters  |  PARIS 

PARIS (Reuters) - France's Sanofi and U.S Regeneron said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers.In a statement, the two companies said they would also accelerate the co-development of dupilumab, a "multi-targeting" drug approved in the United States and Europe to treat eczema and undergoing tests to help treat asthma, nasal polyps, eosinophilic esophagitis and food allergies."The investment in cemiplimab will be increased to $1.64 billion, an increase of ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Mon, January 08 2018. 19:33 IST